Satrajit Roychoudhury

17.3k total citations · 1 hit paper
38 papers, 1.1k citations indexed

About

Satrajit Roychoudhury is a scholar working on Statistics and Probability, Economics and Econometrics and Statistics, Probability and Uncertainty. According to data from OpenAlex, Satrajit Roychoudhury has authored 38 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Statistics and Probability, 9 papers in Economics and Econometrics and 8 papers in Statistics, Probability and Uncertainty. Recurrent topics in Satrajit Roychoudhury's work include Statistical Methods in Clinical Trials (29 papers), Advanced Causal Inference Techniques (9 papers) and Health Systems, Economic Evaluations, Quality of Life (7 papers). Satrajit Roychoudhury is often cited by papers focused on Statistical Methods in Clinical Trials (29 papers), Advanced Causal Inference Techniques (9 papers) and Health Systems, Economic Evaluations, Quality of Life (7 papers). Satrajit Roychoudhury collaborates with scholars based in United States, Switzerland and United Kingdom. Satrajit Roychoudhury's co-authors include Beat Neuenschwander, Heinz Schmidli, David J. Spiegelhalter, Anthony O’Hagan, Sandro Gsteiger, Simon Wandel, Stuart Bailey, Brian P. Hobbs, Fang Chen and Scott Berry and has published in prestigious journals such as Biometrics, Annals of Oncology and Annals of the Rheumatic Diseases.

In The Last Decade

Satrajit Roychoudhury

35 papers receiving 1.1k citations

Hit Papers

Use of historical control data for assessing treatment ef... 2013 2026 2017 2021 2013 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Use of historical control data for assessing treatment effects in clinical trials
    2013 327 citations Kert Viele, Scott Berry et al. Pharmaceutical Statistics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Satrajit Roychoudhury United States 15 772 283 183 110 103 38 1.1k
Lisa V. Hampson United Kingdom 13 469 0.6× 298 1.1× 139 0.8× 119 1.1× 92 0.9× 43 1.0k
Babak Choodari‐Oskooei United Kingdom 13 360 0.5× 216 0.8× 96 0.5× 118 1.1× 61 0.6× 32 849
Ariel Alonso Belgium 18 676 0.9× 313 1.1× 130 0.7× 79 0.7× 32 0.3× 85 1.1k
Mark Chang United States 12 441 0.6× 165 0.6× 179 1.0× 109 1.0× 38 0.4× 48 712
Michael Branson Switzerland 15 1.2k 1.5× 406 1.4× 539 2.9× 151 1.4× 112 1.1× 24 1.6k
Willi Maurer Switzerland 19 1.1k 1.4× 294 1.0× 653 3.6× 175 1.6× 36 0.3× 41 1.4k
Sue‐Jane Wang United States 24 1.4k 1.8× 470 1.7× 727 4.0× 297 2.7× 120 1.2× 73 1.9k
Marc Vandemeulebroecke Switzerland 13 447 0.6× 211 0.7× 124 0.7× 78 0.7× 38 0.4× 36 1.9k
Mario Ouwens United Kingdom 17 242 0.3× 210 0.7× 76 0.4× 69 0.6× 46 0.4× 67 904
Carl‐Fredrik Burman Sweden 14 366 0.5× 171 0.6× 143 0.8× 56 0.5× 22 0.2× 34 584

Countries citing papers authored by Satrajit Roychoudhury

Since Specialization
Citations

This map shows the geographic impact of Satrajit Roychoudhury's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satrajit Roychoudhury with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satrajit Roychoudhury more than expected).

Fields of papers citing papers by Satrajit Roychoudhury

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Satrajit Roychoudhury. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satrajit Roychoudhury. The network helps show where Satrajit Roychoudhury may publish in the future.

Co-authorship network of co-authors of Satrajit Roychoudhury

This figure shows the co-authorship network connecting the top 25 collaborators of Satrajit Roychoudhury. A scholar is included among the top collaborators of Satrajit Roychoudhury based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satrajit Roychoudhury. Satrajit Roychoudhury is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Jialing, Weili He, Joseph C. Cappelleri, et al.. (2025). The hazards of using hazard ratios from proportional hazard models in indirect treatment comparisons. Research Synthesis Methods. 1–15. 1 indexed citations
2.
3.
Corson, Stephen L., Jiang Li, François Mercier, et al.. (2023). Duration of and time to response in oncology clinical trials from the perspective of the estimand framework. Pharmaceutical Statistics. 23(1). 91–106. 2 indexed citations
4.
Lin, Ray, Pralay Mukhopadhyay, Satrajit Roychoudhury, et al.. (2023). Comment on “Non-Proportional Hazards – an Evaluation of the MaxCombo Test in Cancer Clinical Trials” by the Cross-Pharma Non-Proportional Hazards Working Group. Statistics in Biopharmaceutical Research. 15(2). 312–314. 1 indexed citations
5.
Alhadab, Ali, et al.. (2023). Case–control matching‐guided exposure‐efficacy relationship for avelumab in patients with urothelial carcinoma. CPT Pharmacometrics & Systems Pharmacology. 12(12). 2001–2012. 3 indexed citations
6.
Zhou, Tianjian, et al.. (2023). A Tutorial on Modern Bayesian Methods in Clinical Trials. Therapeutic Innovation & Regulatory Science. 57(3). 402–416. 16 indexed citations
7.
Heeg, Bart, Gabriel Tremblay, Ofir Harari, et al.. (2023). Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity. Journal of Comparative Effectiveness Research. 12(3). e220159–e220159. 1 indexed citations
8.
9.
Ren, Jinma, et al.. (2023). Regulatory agilities impacting review timelines for Pfizer/BioNTech’s BNT162b2 mRNA COVID-19 vaccine: a retrospective study. Frontiers in Medicine. 10. 1275817–1275817. 4 indexed citations
10.
Buchanan, J.R., Mengchun Li, Barbara A. Hendrickson, Parul Bhargava, & Satrajit Roychoudhury. (2023). Assessing adverse events in clinical trials during the era of the COVID-19 pandemic. Journal of Biopharmaceutical Statistics. 33(4). 466–475. 2 indexed citations
11.
Kim, Chanmin, et al.. (2022). Assessing treatment benefit in the presence of placebo response using the sequential parallel comparison design. Statistics in Medicine. 41(12). 2166–2190. 1 indexed citations
12.
Kidwell, Kelley M., Satrajit Roychoudhury, Barbara Wendelberger, et al.. (2022). Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles. Orphanet Journal of Rare Diseases. 17(1). 186–186. 18 indexed citations
13.
Zabor, Emily C., Michael J. Kane, Satrajit Roychoudhury, Lei Nie, & Brian P. Hobbs. (2022). Bayesian basket trial design with false-discovery rate control. Clinical Trials. 19(3). 297–306. 3 indexed citations
14.
15.
Roychoudhury, Satrajit & Beat Neuenschwander. (2020). Bayesian leveraging of historical control data for a clinical trial with time‐to‐event endpoint. Statistics in Medicine. 39(7). 984–995. 19 indexed citations
16.
Lin, Ray, Ji Lin, Satrajit Roychoudhury, et al.. (2020). Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis. Figshare. 30 indexed citations
17.
Quiroz, Jorge, et al.. (2019). A comparative study of confidence intervals to assess biosimilarity from analytical data. Pharmaceutical Statistics. 18(3). 316–328. 2 indexed citations
18.
Kaizer, Alexander, Joseph S. Koopmeiners, Michael J. Kane, et al.. (2019). Basket Designs: Statistical Considerations for Oncology Trials. JCO Precision Oncology. 3(3). 1–9. 20 indexed citations
19.
Viele, Kert, Scott Berry, Beat Neuenschwander, et al.. (2013). Use of historical control data for assessing treatment effects in clinical trials. Pharmaceutical Statistics. 13(1). 41–54. 327 indexed citations breakdown →
20.
Quiroz, Jorge, Jeffrey R. Wilson, & Satrajit Roychoudhury. (2012). Statistical analysis of data from dilution assays with censored correlated counts. Pharmaceutical Statistics. 11(1). 63–73. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lisa V. Hampson Breakdown of academic impact, for papers by Babak Choodari‐Oskooei Breakdown of academic impact, for papers by Ariel Alonso Breakdown of academic impact, for papers by Mark Chang Breakdown of academic impact, for papers by Michael Branson Breakdown of academic impact, for papers by Willi Maurer Breakdown of academic impact, for papers by Sue‐Jane Wang Breakdown of academic impact, for papers by Marc Vandemeulebroecke Breakdown of academic impact, for papers by Mario Ouwens Breakdown of academic impact, for papers by Carl‐Fredrik Burman
Rankless by CCL
2026